Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

CompletedOBSERVATIONAL
Enrollment

355

Participants

Timeline

Start Date

November 9, 2017

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Alectinib

According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).

Trial Locations (37)

10380

Inje University Ilsan Paik Hospital, Gyeonggi-do

11765

Uijeongbu St. Mary's Hospital, Gyeonggi-do

13496

CHA Bundang Medical Center, Gyeonggi-do

14068

Hallym University Sacred Heart Hospital, Gyeonggi-do

14647

Bucheon St Mary's hospital, Gyeonggi-do

16247

St. Vincent's Hospital, Gyeonggi-do

21431

Catholic Univ. of Incheon St.Mary's Hospital, Incheon

21565

Gachon University Gil Medical Center, Incheon

22332

Inha University Hospital, Incheon

26426

Yonsei University Wonju Severance Christian Hospital, Gangwon-do

28644

Chungbuk National University Hospital, Cheongju-si

35365

Konyang University Hospital, Daejeon

41404

Kyungpook National University Chilgok Hospital, Daegu

41931

Keimyung University Dongsan Medical Center, Daegu

42472

Daegu Catholic University Medical Center, Daegu

47392

Inje University Busan Paik Hospital, Busan

49201

Dong-A University Hospital, Busan

49241

Pusan National University Hospital, Busan

49267

Kosin University Gospel Hospital, Busan

50612

Pusan National University Yangsan Hospital, Gyeongsangnam-do

54907

Chonbuk National University Hospital, Jeollabuk-do

58128

Chonnam National University Hwasun Hospital, Jeollanam-do

Unknown

Dongnam Institute of Radiological & Medical Sciences, Busan

01757

Inje University, Sanggye-Paik Hospital, Seoul

02447

Kyung Hee University Hospital, Seoul

02841

Korea University Anam Hospital, Seoul

03181

Kangbuk Samsung Hospital, Seoul

03722

Severance Hospital, Yonsei University, Seoul

Severance Hospital, Seoul

05278

Gangdong Kyung Hee University Hospital, Seoul

05505

Asan Medical Center, Seoul

06273

Gangnam Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

07985

Ewha Womans University Mokdong Hospital, Seoul

08308

Korea University Guro Hospital, Seoul

140-743

Soon Chun Hyang University Hospital; Department of Pulmonology and Allergy, Seoul

220-701

Yonsei University Wonju Severance Christian Hospital, Wŏnju

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03271554 - Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea | Biotech Hunter | Biotech Hunter